NextPlat Corp filings document a public operating company with healthcare operations, e-commerce operations, common stock, and warrants. Its Form 8-K reports cover operating and financial results, preliminary business updates, Nasdaq listing compliance, amendments to corporate charter documents, and capital-structure matters such as reverse stock split mechanics and warrant or equity-plan adjustments.
Proxy statements and governance filings describe shareholder voting matters, board and executive compensation disclosures, equity awards, and related corporate-governance procedures. Other material-event filings address executive employment arrangements and disclosures tied to the company’s pharmacy services, healthcare data management, prescription fulfillment, and e-commerce communications products.
NextPlat Corp (NXPL) reported revenue of $32.235 million for the nine months ended September 30, 2026, down 21% from $40.918 million in the comparable 2025 period. Net loss narrowed to $2.024 million from $5.916 million; gross profit rose to $11.784 million from $8.477 million, and operating cash use was $2.065 million versus $5.828 million.
Healthcare prescription revenue fell while pharmacy contract revenue increased. On October 30, Oscar-plan claims were suspended at PharmcoRx’s Hallandale Beach location until Oscar’s investigation is resolved or further notice; NextPlat expects revenue to decline about $0.3 million monthly during the suspension. NextPlat completed a $1.5 million cash acquisition of Scott’s Pharmacy on October 1.
Management concluded its plans alleviate substantial doubt about going concern. As of September 30, 2026, NextPlat maintained a $1.75 million accrual for a putative class action concerning October 2024 merger consideration, brought by former Progressive Care Inc. Chief Executive Officer and Chairman Alan Jay Weisberg against NextPlat, former NextPlat Chief Executive Officer and Executive Chairman Charles M. Fernandez, and NextPlat director Rodney Barreto. The court denied a motion to dismiss on December 3, 2025; class-certification argument is scheduled for January 7, 2027.
NextPlat Corp (NXPL) reported third-quarter 2026 revenue of $10.499 million, down from $13.752 million a year earlier. Gross profit increased to $3.678 million from $2.730 million, a nearly 35% rise, while consolidated gross margin was 35.0% versus 19.9%. Net loss attributable to common stockholders narrowed approximately 66% to $748,000, or a loss of $0.28 per diluted share, from $2.185 million, or a loss of $0.84 per diluted share.
Healthcare pharmacy contract revenue increased 300% to approximately $2.4 million from $0.6 million, while pharmacy prescription revenue was approximately $4.3 million versus $9.5 million. Healthcare gross margin was approximately 41%, compared with 18%, and e-commerce revenue rose 3% to approximately $3.8 million. 340B prescription volumes grew nearly 72% year over year. The company added three 340B services contracts; onboarding is underway and is expected to contribute revenue in early 2027.
As of September 30, 2026, cash was $11.220 million and working capital was approximately $13.5 million; the company reported no material unsecured debt. It completed the Scott’s pharmacy acquisition immediately after quarter-end and announced a Jacksonville location. A nationwide medication-fulfillment website is on track to launch in the fourth quarter of 2026.
NextPlat Corp Chief Compliance Officer Robert Phillip Bedwell Jr. acquired 1,250 shares of common stock on October 14, 2026, in a grant or award transaction. The shares were held directly, and his reported direct common stock holdings after the transaction were 3,753 shares. This was reported as an acquisition, not a market purchase or sale.
NextPlat Corp (NXPL) Chief Financial Officer Amanda Ferrio acquired 3,000 shares of common stock through a grant on October 14, 2026. Her reported direct holdings after the award were 6,750 shares. The reported price was $0.0000 per share; this was a compensation-related award, not a market purchase.
NextPlat Corp (NXPL) reported that Chief Executive Officer and director David Phipps acquired 6,000 shares of Common Stock through a grant or award on October 14, 2026. The transaction was reported at $0.0000 per share, and his directly held position afterward was 73,178 shares. This was an award acquisition rather than a reported market purchase.
NextPlat Corp director Anthony Armas reported an indirect award acquisition of 661 common shares by Apollo Two MSO, LLC on September 30, 2026, at a reported price of $0.00 per share. The reported post-transaction holding was 12,935 shares, after giving effect to the 1-for-10 reverse stock split that went into effect on April 13, 2026. No Rule 10b5-1 plan is reported.
NextPlat Corp (NXPL) director Rodney Barreto acquired 1,323 shares of Common Stock through a grant or award on September 30, 2026. The transaction row lists a price of 0.0000 per share. His direct holdings following the transaction were 50,199 shares; the footnote says this post-transaction amount reflects the 1-for-10 reverse stock split that took effect on April 13, 2026.
On September 30, 2026, NextPlat Corp director Douglas Ellenoff acquired 1,323 shares of common stock as a grant or award, at a reported price of $0.00 per share. He directly held 22,259 shares after the transaction. The footnote says these amounts reflect the 1-for-10 reverse stock split that took effect April 13, 2026.
NextPlat Corp (NXPL) completed its acquisition of an independent pharmacy in a rural community near Pensacola, Florida, and its inventory for total cash consideration of $1,485,439. For the year ended December 31, 2025, the pharmacy generated approximately $5.6 million in sales.
The pharmacy was profitable, maintained positive working capital and operated with a debt-free balance sheet. NextPlat expects it to contribute to continued growth and profitability in the PharmcoRx healthcare segment throughout the fourth quarter. PharmcoRx currently operates five pharmacies serving patients in northern, central and southern Florida.
NextPlat Corp reported lower revenue but sharply improved profitability for the three and six months ended June 30, 2026. Quarterly revenue fell to $11.9 million from $13.2 million, and year‑to‑date revenue declined to $21.7 million from $27.2 million, driven mainly by reduced healthcare prescription volumes and reimbursement rates. e‑Commerce revenue was roughly flat.
Mix shift and new contracts significantly improved margins. Gross margin rose to 40% in the quarter and 37% year‑to‑date, versus 22% and 21% a year earlier, helped by higher‑margin 340B and medication‑fulfillment contracts and the Medicare Maximum Fair Price program. Net loss narrowed to $0.1 million for the quarter and $1.3 million year‑to‑date, from $1.8 million and $3.7 million, respectively.
The company held $11.9 million of cash and $14.2 million of working capital, and has $3.8 million of remaining capacity under an at‑the‑market equity program. Management concluded that these resources and its plans alleviate prior substantial doubt about continuing as a going concern. NextPlat also recorded a $1.75 million legal accrual related to a Delaware class action and disclosed ongoing material weaknesses in internal control, along with a $0.4 million liquidated‑damages obligation under a registration rights agreement.